Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Veritas In Silico Inc. ( (JP:130A) ).
Veritas In Silico Inc. outlined a future growth strategy centered on transforming into a specialty pharma company by enhancing and deploying its evolved aibVIS AI-driven drug discovery platform. The company plans to accelerate mRNA-targeted drug development, strengthen its intellectual property, advance its proprietary drug delivery system for nucleic acid therapies, and pursue strategic alliances in adjacent markets, supporting a hybrid business model that combines platform services with its own therapeutic pipelines.
These initiatives are designed to broaden revenue sources beyond traditional pharma licensing and solidify Veritas In Silico’s position in the emerging mRNA and nucleic acid therapeutics space. By expanding its technology applications to areas such as agrochemicals and medical devices while building a robust pipeline, the company aims to boost mid- to long-term corporate value and secure a more prominent role in the global life sciences ecosystem.
More about Veritas In Silico Inc.
Veritas In Silico Inc. is a Japan-based biotechnology company focused on mRNA-targeted drug discovery. Leveraging its proprietary aibVIS platform, which integrates multiple specialized AI modules, the company aims to develop high-value nucleic acid therapeutics and expand into adjacent fields such as agrochemicals and medical devices.
Average Trading Volume: 222,000
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.17B
Find detailed analytics on 130A stock on TipRanks’ Stock Analysis page.